CAMBRIDGE, Mass.–(BUSINESS WIRE)–November 18, 2013– InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that Christopher McNulty has been appointed as Vice President, Business Development.
Most recently, Mr. McNulty served as Senior Director of Business Development at Repligen Corporation, where his responsibilities included out-licensing programs for rare neurodegenerative diseases. Previously, he was Director of Corporate Development at Seventh Sense Biosystems and Associate Director of Business Development and Alliance Management at Genzyme Corporation. While at Genzyme, he led business development activities in the area of neurology. Before joining Genzyme, Mr. McNulty held technical roles at Transform Pharmaceuticals and Cereon Genomics. He has an MBA from Harvard Business School, and BS and MEng degrees from MIT, where he performed research on biological hydrogels.
Michael Astrue, the interim CEO of InVivo, stated, “Going forward we expect our growth to be driven primarily by our success as a drug delivery company. In particular, our proprietary technology that can deliver proteins and other molecules locally on a time-release basis can provide significant value to most major pharmaceutical companies and biotech companies. Chris will be a key part of our transformation.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. focuses on utilizing polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.